Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 20.25 GBp
Change Today 0.00 / 0.00%
Volume 516.8K
TRX On Other Exchanges
Symbol
Exchange
London
Berlin
As of 12:15 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

tissue regenix group plc (TRX) Snapshot

Open
20.25 GBp
Previous Close
20.25 GBp
Day High
20.25 GBp
Day Low
20.25 GBp
52 Week High
07/31/14 - 28.00 GBp
52 Week Low
04/14/15 - 14.50 GBp
Market Cap
153.8M
Average Volume 10 Days
427.1K
EPS TTM
-0.01 GBp
Shares Outstanding
759.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TISSUE REGENIX GROUP PLC (TRX)

Related News

No related news articles were found.

tissue regenix group plc (TRX) Related Businessweek News

No Related Businessweek News Found

tissue regenix group plc (TRX) Details

Tissue Regenix Group Plc, a medical devices company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United Kingdom and the United States. The company’s patented decellularisation (dCELL) technology process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which can be used to repair diseased or worn-out body parts. The dCELL technology has applications in various clinical needs, such as wound care, heart valve replacement, and knee repair. It offers DermaPure, a decellularized human dermis product used to cover chronic wounds; and vascular patches for peripheral vascular reconstruction. The company also develops OrthoPure category products, which include meniscus products used to repair damages in the meniscus knee cartilage, as well as tendon products for anterior cruciate ligament repairs. In addition, it develops CardioPure HV, a human heart valve product. Tissue Regenix Group Plc was incorporated in 2006 and is based in York, the United Kingdom.

60 Employees
Last Reported Date: 05/11/15
Founded in 2006

tissue regenix group plc (TRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 248.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 179.0K GBP
Compensation as of Fiscal Year 2015.

tissue regenix group plc (TRX) Key Developments

TRX Wound Care Inc. Signs an Additional Regional Distribution Agreement for DermaPure with Tissue Regenix Group plc

Tissue Regenix Group plc announced that TRX Wound Care Inc. has signed an additional regional distribution agreement for DermaPure. This agreement has been signed with an experienced local surgical and wound care distributor who will cover one of the 12 states in the Novitas Medicare administrative jurisdiction. The partnership is expected to be worth a minimum of $135,000 over the next 12 months and follows the signing of the first regional distributor agreement, covering two states in the jurisdiction, which is expected to be worth a minimum of $600,000 over the next 12 months.

Tissue Regenix Group Plc Announces Further Medicare Coverage Approval for DermaPure®

Tissue Regenix Group plc announced that it has secured approval from the Noridian Healthcare Solutions and Palmetto GBA Medicare administrators for DermaPure® reimbursement. The approval from Noridian Healthcare Solutions and Palmetto GBA means that DermaPure® is now available to 20.7 million Medicare beneficiaries across 30 states and follows previously announced approvals from the Novitas Solutions and CGS Administrators jurisdictions in 2015. Gaining Medicare approval for DermaPure® across the United States is a key element of Tissue Regenix's strategy for full commercialisation of the product and allows the company to access the large potential group of US patients who would be unable to benefit from Tissue Regenix products without it. The Medicare programme in the United States is a national social insurance programme which provides health insurance for citizens aged 65 and over. It is administered by bodies such as Noridian Healthcare Solutions and Palmetto GBA, each one with their own jurisdiction of states. When coverage is approved it enables medical establishments to purchase and seek reimbursement for products used to treat post-acute and outpatients who are beneficiaries of the Medicare initiative.

Tissue Regenix Group Plc, Annual General Meeting, Jun 12, 2015

Tissue Regenix Group Plc, Annual General Meeting, Jun 12, 2015., at 10:00 GMT Standard Time. Location: DLA Piper UK LLP, Princes Exchange. Agenda: To receive the company's annual accounts, strategic report and directors' and auditors' reports for the year ended 31 January 2015; to reappoint John Samuel, who retires by rotation, as a director of the Company; to reappoint Antony Odell, who retires by rotation, as a director of the Company; to reappoint Alan Miller, who retires by rotation, as a director of the Company; to reappoint KPMG LLP as auditors of the Company; to authorise the directors to determine the remuneration of the auditors; and to transact such other business issues.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRX:LN 20.25 GBp 0.00

TRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRX.
View Industry Companies
 

Industry Analysis

TRX

Industry Average

Valuation TRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,295.0x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,542.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE REGENIX GROUP PLC, please visit www.tissueregenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.